585 - 18F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

Molecular Targeting Probes - Radioactive & Nonradioactive -> Novel Radiochemistry & Chelation 585

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

Session Name

New Radiochemistry Methodology

Speakers

J. Wright

Authors

Presentation Topic

Molecular Targeting Probes - Radioactive & Nonradioactive -> Novel Radiochemistry & Chelation

Presentation Number

585

Previous Eposter

583 - Nucleophilic radiofluorination of aryl halides with K¹⁸F mediated by well-defined copper complexes (ID 1242)

Next Eposters

586 - A general ¹¹C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

587 - MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer (ID 1246)

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

593 - Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (ID 777)

594 - Hematotoxicity after Radioligand Therapy with ¹⁷⁷Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic ¹⁷⁷Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)

598 - Bridging brain structural/functional connectivity and tau load in PSP: A [18F]PI-2620 PET/MRI study (ID 855)

600 - Interaction of Striatal Dopaminergic and Cholinergic Activity in Parkinson Disease: A Multimodal Imaging Study Based on ¹¹C-DTBZ and ¹⁸F- FEOBV PET Combined with Diffusion Tensor Imaging (ID 856)

585 - 18F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

585 - 18F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

Previous Eposter

583 - Nucleophilic radiofluorination of aryl halides with K18F mediated by well-defined copper complexes (ID 1242)

Next Eposters

586 - A general 11C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

587 - MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer (ID 1246)

588 - 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel 177Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

593 - Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (ID 777)

594 - Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic 177Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)

598 - Bridging brain structural/functional connectivity and tau load in PSP: A [18F]PI-2620 PET/MRI study (ID 855)

600 - Interaction of Striatal Dopaminergic and Cholinergic Activity in Parkinson Disease: A Multimodal Imaging Study Based on 11C-DTBZ and 18F- FEOBV PET Combined with Diffusion Tensor Imaging (ID 856)

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

585 - ¹⁸F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy (ID 1241)

583 - Nucleophilic radiofluorination of aryl halides with K¹⁸F mediated by well-defined copper complexes (ID 1242)

586 - A general ¹¹C-carboxylation approach mediated by fluoride-desilylation of organosilanes (ID 1239)

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

591 - Early prostate-specific antigen changes and clinical outcome following ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

594 - Hematotoxicity after Radioligand Therapy with ¹⁷⁷Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic ¹⁷⁷Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)

600 - Interaction of Striatal Dopaminergic and Cholinergic Activity in Parkinson Disease: A Multimodal Imaging Study Based on ¹¹C-DTBZ and ¹⁸F- FEOBV PET Combined with Diffusion Tensor Imaging (ID 856)